• 2011 Program

• 2011 Block Program

• 2011 Speakers

program

QUESTIONS?

Click here to read FAQ
regarding the program.



Robert Lee Kilpatrick
Partner

Phone:
+1.831.464.4230

17:30-19:30  Early Check-in & Registration - Ground Floor

Visit the registration desk to check in on Sunday, which allows you to jump-start your networking opportunities at the Welcome Reception!

By registering early, you'll be able to collect your name badge, program, and handbag materials and avoid long lines on Monday morning.

17:30-19:30  Welcome Reception - Benjamin Britten Lounge, 3^rd Floor

You are invited to attend the opening reception of the 19^th Annual BioPartnering Europe. After checking in at Registration, join us on the 3^rd floor for drinks and delicious hors d'œuvres.

07:30-16:00  Registration - Ground Floor

08:00-09:00  Continental Breakfast - Benjamin Britten Lounge, 3^rd Floor

Join us for an energizing continental breakfast of fresh orange juice, muffins and breakfast pastries. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.

09:00-09:15  Welcome Address | Part 1 - Whittle Room, 3^rd Floor

Title: BioPartnering Europe is Evolving into BioPartnering Future Europe 2012

BioPartnering Europe (BPE) is Europe's longest running biopharma partnering event. Launched in 1993, BPE has an unbroken record of achievement. The event has facilitated partnerships between thousands of biopharma companies, many of which have become the most important drivers of innovation in Europe, and elsewhere. In its 20th anniversary year - 2012 - BPE is being transformed into BioPartnering (Future) Europe (BPFE) 2012 in Brussels. The word "Future" has been added to the event title to reflect the European Commissions ambitious goals of making the life sciences a central element in the continuing transformation of Europe into a leading "knowledge economy".

BPFE has been designed as a platform for ALL of EUROPE to come together in one place: for European companies and institutions to partner with each other, and with the rest of the world, particularly the USA, Canada, China, India, Japan, Korea, Australia, Latin America, Israel, Russia and other emerging regions. BPFE will also provide a platform for SMEs that currently do not attend any partnering events in Europe, and to that end we will build in more programing to address the crucial need for new sources of funding.

In its 20th anniversary year, BioPartnering (Future) Europe 2012 will be held in Brussels, the home of the European Commission, EuropaBio, the European Biotech Network, and a vibrant life science cluster, comprised of Wallonia, Flanders and Brussels. Together with most of the European National Biotechnology Associations, BPFE is poised to be a driver of the growth and development of the European life sciences industry.

Speaker: Dr. Robert Lee Kilpatrick, Partner, TVG

09:00-09:15  Welcome Address | Part 2 - Whittle Room, 3^rd Floor

Title: Welcome To Brussels in 2012

Belgium will host BioPartnering Future Europe 2012 in Brussels, October 7-9, 2012. This is an ideal setting for Europe's longest running biopharma event because Belgium makes a substantial contribution to European competitiveness in this industrial sector. Although the country represents only 3% of the economy of the EU27, it accounted for 17% of EU exports of biopharmaceuticals in 2008. In 2009, the Belgian trade balance for pharmaceuticals was in large surplus (€7,216,415), and exports grew by 11.76% between 2008 and 2009. In addition, Belgium accounts for a remarkably high proportion of Europe's turnover in biotechnology. It represents 16% of the European biopharmaceutical industry, making our country a key player at world level. The biotechnology sector is vast and covers a wide range of industries. This study includes companies that meet the sectoral definition used by the OECD: "The application of science and technology to living organisms, as well as parts, products and models thereof, to alter living or non-living materials for the production of knowledge, goods and services". Based on this definition, 17% of the country's 308 biotech businesses are concentrated within Brussels itself, while Flanders and Wallonia host 49% and 34% respectively.

It is easy to travel from the UK to Belgium in 1 hour 51 mins via Eurostar.

Speaker: Dr. Johan VanHemelrijk, Secretary General, Bio.be

09:15-09:45  BIA Keynote Address - Whittle Room, 3^rd Floor

Title: The UK as a Supercluster and the Importance of Getting a Britrail Pass!

The geographic size of New England, the UK is blessed with an unparalleled collection of world class scientific institutions and London as a magnet for global corporates and investors.  The UK needs to be on everyone’s radar screens.

Speaker: Mr. Nigel Gaymond, Chief Executive, BioIndustry Association (BIA)

09:45-10:15  AstraZeneca Keynote Address - Whittle Room, 3^rd Floor

Title: The Search for Innovation in Healthcare: Companion diagnostics are the new frontier

Partnership and collaboration are at the core of AstraZeneca’s personalised healthcare strategy.  Hear from Bob Holland, Head of Personalised Healthcare & Biomarkers, Innovative Medicines, AstraZeneca our strategy and philosophy to enhance innovation through personalised healthcare and through partnering.  Bob will highlight several ongoing collaborations, but No single partner can address all of our PHC needs so we are looking for a series of partnerships to help us to achieve our aims.

Speaker: Dr. Robert Holland, Head of Personalised Healthcare & Biomarkers, Innovative Medicines, AstraZeneca

10:15-10:45  Pfizer Keynote Address - Whittle Room, 3^rd Floor

Title: Patients as Partners – the Power of Patient Engagement

Patients and their data drive medical research but their participation is often limited to the role of “subject” in clinical studies or “consumer” of products. What value are we missing by not including patients as an equal voice in the development of new therapies from research, to clinical trials, to the market? How can we engage patients in shaping policies that unleash the power of innovation and result in better treatments, shorter timelines, and greater access.

Hear from Greg Simon, Senior Vice President, Patient Engagement, Pfizer Inc. on strategies to change the role of patients in drug development and make industry commitment to patients a vital partnership that drives business and better health.

Speaker: Mr. Greg Simon, Senior Vice President, Patient Engagement, Pfizer Inc.

10:45-11:15  European Commission Keynote Address - Whittle Room, 3^rd Floor

Title: EC Steps Up Support for Innovation by Funding More Industry-led Research

The FP7 programme is intended to support the competitiveness of European industries and services by fostering genuine industry-academia collaborations. In July 2011, the European Commission's published its 2012 work programme with a €656 million budget for health research grants in the coming financial year. Half of the funds are earmarked for "SME-targeted" or broader "industry-targeted" projects. Already last year the Commission had set aside one third of the €661m budget for such projects, leading to the funding of 34 projects – half of them led by small companies – with a total of €221 million in grants. This is almost twice the level of funding of previous years and it is intended to grow further in 2012 and 2013. Stéphane Hogan will illustrate the benefits of this support and what is required to obtain grants.

Speaker: Mr. Stéphane Hogan, Head of Unit, Horizontal Aspects Health Research, European Commission - DG Research & Innovation

11:15-11:45  EuropaBio Keynote Address - Whittle Room, 3^rd Floor

Title: Driving Innovation in Europe Through Collaboration

No where better than in a Business Partnering Event like BPE is it clear to all that innovation, its creation, support and success through collaboration is at the heart of responding to patients' needs today. Europe needs to strengthen cross-border and cross-discipline R&D for healthcare and healthcare biotech while providing the right environment for the results of those R&D efforts to be realised in Europe in truly innovative collaborative ventures. For innovation to thrive, the right conditions need to be in place throughout the product chain, from invention with IP and seed capital availability to the right talent and differentiated capital in the development phase to the right legislation facilitating access of safe and innovative products to the patient in the EU market not to mention true value for innovation at the Member State level.

Speaker: Mrs. Nathalie Moll, Secretary General, EuropaBio

11:15-17:30  Exhibition | Spotlight on Biotechnology - Benjamin Britten Lounge, 3^rd Floor

Connect with leading biotechnology companies, services and regions during a two-day span during which they will be showcased.

. Current Partnering - United Kingdom
. Current Agreements - United Kingdom
. Deloitte Recap LLC - USA
. Hungarian Investment and Trade Agency (HITA) - Hungary
. Health Protection Agency - United Kingdom
. AWEX - Wallonia Foreign Trade and Investment Agency - Belgium
. University of Nottingham - United Kingdom
. Trinity College Institute of Neuroscience (TCIN) - Ireland
. Merrill Datasite - United Kingdom
. EuropaBio - Belgium
. UBIFrance - United Kingdom
. TransPerfect Trial Interactive - USA
. Flanders Investment & Trade - Belgium
. Cancer Research UK - United Kingdom
. International Trade Branch, Ontario Ministry of Economic Development and Trade - Canada
. Brussels Life Tech - Belgium

11:15-17:30  Face-to-Face Meetings | powered by biopartnering.com™ - Fleming room, 3^rd Floor

All meetings scheduled through biopartnering.com will be held at the numbered booths and lettered tables in the Fleming Room (3rd Floor). Please visit the onsite Meeting & Message Desks for assistance.

11:30-12:30  Workshop 1 | European Biotechnology Network - Guild Room, 3M Floor

Title: Financing Partnerships in Healthcare Biotechnology

This critical workshop discusses how partners of all shapes and sizes can fund international partnerships – Europe and North America are top priority for partnerships and the session explores funding from Europe (European Commission) and the US (NIH and Department of Defense) that covers company research and exploitation within international partnerships. As the European Commission in particular becomes increasingly company-oriented, the time is right to access industry-driven grants of up to €12 million that extend as far as Phase II clinical trials.

Chair: Mr. Stéphane Hogan, Head of Unit, Horizontal Aspects Health Research, European Commission - DG Research & Innovation
Speaker: Dr. Astrid Hoebertz, National Contact Point (NCP) of Health FP7, FFG - Austrian Research Promotion Agency
Speaker: Dr. Hugh Laverty, Scientific Project Manager, Innovative Medicines Initiative
Speaker: Dr. David Reynolds, External Research and Development Innovation, Pfizer

12:00-12:30  Podium Presentations | Stream 1 - Abbey Room West, 4^th Floor

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

12:00 Affitech AS - Norway
12:15 Vironova AB - Sweden

12:00-12:30  Podium Presentations | Stream 2 - Abbey Room East, 4^th Floor

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

12:00 Engram Translational Neuroscience - Ireland
12:15 Merrion Pharmaceuticals - Ireland

12:00-12:30  Podium Presentations | Stream 3 - Henry Moore East, 4^th Floor

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

12:00 Antisense Pharma GmbH - Germany
12:15 Amakem NV - Belgium

12:00-12:30  Podium Presentations | Stream 4 - Henry Moore West, 4^th Floor

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

12:15 BioDiem Ltd - Australia

12:30-13:30  Hot Buffet Lunch - Seated: 5^th Floor | Standing: 3^rd Floor

Refresh yourself with a delicious hot lunch buffet.

Seated: Elizabeth Windsor Room, 5^th Floor
Standing: Benjamin Britten Lounge, 3^rd Floor

13:30-16:30  Podium Presentations | Stream 1 - Abbey Room West, 4^th Floor

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

13:30 4-Antibody AG - Switzerland
13:45 AcelRx - USA
14:00 Mirna Therapeutics - USA
14:15 Insituvue, Inc. - USA
14:45 Applied Integrin Sciences, Inc. - USA
15:00 Acucela Inc. - USA
15:15 Health Protection Agency - United Kingdom
15:45 HemaQuest Pharmaceuticals, Inc. - USA
16:00 ValiRx plc - United Kingdom
16:15 Crescendo Biologics Ltd - United Kingdom

13:30-16:30   Podium Presentations | Stream 2 - Abbey Room East, 4^th Floor

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

13:30 CYTAVIS BioPharma GmbH - Germany
13:45 ARC Medical Devices Inc. - Canada
14:00 AngioChem Inc - Canada
14:15 3D - PharmXchange - Netherlands
14:30 CDG Therapeutics - USA
14:45 Genfit - France
15:00 Trevena, Inc. - USA
15:15 Kyorin Europe GmbH - Germany
15:30 Kymab Ltd. - United Kingdom
15:45 Dicerna Pharmaceuticals - USA
16:00 Delenex Therapeutics AG - Switzerland
16:15 PolyTherics Ltd - United Kingdom

13:30-16:30  Podium Presentations | Stream 3 - Henry Moore East, 4^th Floor

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

13:30 ImmusanT, Inc. - USA
13:45 Life Chemicals Inc - Canada
14:00 PolyMedix, Inc. - USA
14:15 SARcode Bioscience - USA
14:30 InVasc Therapeutics, Inc - USA
14:45 Bioject Medical Technologies - USA
15:15 ChanTest Corporation - USA
15:30 Horizon Pharma Inc - USA
15:45 MorphoSys AG - Germany
16:00 Koronis Pharmaceuticals - USA
16:15 Oxford BioMedica plc - United Kingdom

13:30-16:30  Podium Presentations | Stream 4 - Henry Moore West, 4^th Floor

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

13:30 Mithridion, Inc - USA
13:45 Dyax Corp. - USA
14:00 Fluorinov Pharma Inc. - Canada
14:15 Mucosis B.V. - Netherlands
14:30 Sernova Corp - Canada
14:45 Antibe Therapeutics - Canada
15:00 ArcticDx Inc. - Canada
15:15 Axela Inc. - Canada
15:30 Spinifex Pharmaceuticals - Australia
15:45 Circadian Technologies Limited - Australia
16:00 Biosceptre International Limited - Australia
16:15 Benitec Ltd - Australia

16:30-17:30  Workshop 2 | European Biotechnology Network - Guild Room, 3M Floor

Title: Building Partnerships in Healthcare Biotechnology

This workshop from the European Biotechnology Network looks at the types of partnerships that drive product development in Europe. The workshop hears from pharma, biotech and academic partnerships with the mission to understand how to create the right partnership and make it work for you. Speakers include pharma and biotech companies discussing the partnerships that work for them and top tips on creating an effective relationship.

This workshop is supported by funding experts available for partnering meetings throughout BPE.

Chair: Dr. Claire Skentelbery, Secretary General, European Biotechnology Network
Speaker: Dr. Luca Bolliger, Head, Director of Business Development, NovImmune
Speaker: Dr. Eric Halioua, Chief Executive Officer, Promethera Biosciences
Speaker: Dr. Manfred Horst, Director, Scientific Liaison, Licensing and External Research Europe , Merck/MSD
Speaker: Mr. Jordi Naval, Chief Executive Officer and Founder, Anaxomics

16:30-17:30  Leadership Session 1 | Goodwin Procter - Whittle Room, 3^rd Floor

Title: Finance - State of the European Markets and Where are they going with Venture Capital, Private Investors, Pharma Venture in Europe and Globally

Biotechs in both the United States and Europe are now looking to each other for potential sources of venture capital. US biotechnology companies are taking their tech to Europe, while European companies continue to migrate to the U.S. in search of funding. Which side offers the greater advantage to biotech companies seeking capital? Is it easier to obtain funding in Europe or the U.S.? Global funding opportunities also exist as investors in China, India and Latin America begin to move into the sector – what are the possibilities outside of the traditional funding markets?

Chair: Dr. Kingsley Taft, Partner, Goodwin Procter LLP
Speaker: Dr. Jeffrey Moore, Vice President, MP Healthcare Venture Management, Inc.
Speaker: Mr. Peter Reikes, Vice Chairman of Healthcare Investment Banking, Stifel Nicolaus
Speaker: Dr. Mårten Steen, Partner, HealthCap

17:45-18:30  Bus Transportation to Reception - Front of QEII Conference Centre Lobby

Coaches will transport delegates to the Saatchi Gallery for the networking reception.

The first coach will depart the QEII Conference Centre Lobby at 17:45. Consequent shuttles will depart every 15 minutes with the final shuttle departing at 18:30.

Buses return to select hotels in the QEII Conference Centre vicinity beginning at 19:00.

18:15-20:00  Networking Reception at the Saatchi Gallery - Duke of York's HQ, Sloane Square

Title: Reception sponsored by AstraZeneca

Join us at the Saatchi Gallery for a relaxing evening of contemporary art, wine and delicious hors d'oeuvres.

The Saatchi Gallery occupies the entire 70,000 square feet of the magnificent Duke of York’s HQ. The Gallery's elegant interior provides an ideal, casual networking environment.

07:30-16:00  Registration - Ground Floor

08:00-09:00  Continental Breakfast - Benjamin Britten Lounge, 3^rd Floor

Join us for an energizing continental breakfast of fresh orange juice, muffins and breakfast pastries. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.

09:00-09:30  Deloitte Recap Keynote Address - Whittle Room, 3^rd Floor

Title: How are Today’s Market Influences Affecting Biopharma Deals?

 

Faced with the limited availability and high cost of private capital, weak public markets and increasing pressure toward acquisition, are emerging biopharma companies doing deals differently? Drawing upon the more than 35,000 deals catalogued and analyzed in their DEAL builder™ database, Deloitte Recap will endeavor to answer this question, suggesting some new analytical tools in the process.

Speaker: Mr. Michael Johnson, Practice Leader, Deloitte Recap

09:30-10:00  Merck Keynote Address - Whittle Room, 3^rd Floor

Title: The State of the Art: The Ever-Changing Dealmaking Landscape

Licensing has become increasingly critical to our industry as Pharma heats up its search for innovation and Biotech achieves success in discovery and development. Shifts in dealmaking practices and perspectives are substantial -- but what does it mean and, more importantly, where will we end up? Industry veteran Barbara Yanni will provide her take on the current market challenges, the changes she has seen in licensing practices throughout her career and what it means for today's dealmakers.

Speaker: Ms. Barbara Yanni, Vice President and Chief Licensing Officer, Merck/MSD

10:00-11:15  Leadership Session 2 | Ferghana Partners - Whittle Room, 3^rd Floor

Title: SMEs That Have Gotten Really Good Deals. What Worked and Why

Europe! This geographic term covers substantial heterogeneity in territory, cultures, languages and, of course, biotech companies and their deals. The panel, consisting of six people and a moderator (the great biotech guru William Kridel), is organized into three pairs of diverse companies for three differentiated deals: Europe-Europe, Europe-US, Europe-Asia. The panelists will comment from their opposing viewpoints as to why the deal was done, the benefits that it has brought or is expected to bring, problems that were overcome in the transaction negotiating process, and lessons for the BPE audience.

Chair: Mr. William Kridel, Managing Director, Ferghana Partners Group
Speaker: Mr. John Adamou, Head, US Strategic Transactions & Alliance Management, Boehringer Ingelheim GmbH
Speaker: Dr. Mark Carlton, President & Chief Scientific Officer, Takeda Cambridge Limited
Speaker: Dr. Kevin Fitzgerald, Chief Executive Officer, FStar
Speaker: Dr. Peter Nell, Director, Global Innovation Sourcing, Bayer HealthCare Pharmaceuticals
Speaker: Mr. Sunil Patel, Senior Vice President, Corporate Development, OncoMed Pharmaceuticals, Inc.
Speaker: Dr. Malcolm Weir, Chief Executive Officer, Heptares Therapeutics Ltd.

10:00-16:00  Face-to-Face Meetings | powered by biopartnering.com™ - Fleming room, 3^rd Floor

All meetings scheduled through biopartnering.com will be held at the numbered booths and lettered tables in the Fleming & Whittle Rooms (3rd Floor). Please visit the onsite Meeting & Message Desks for assistance.

10:00-16:00  Exhibition | Spotlight on Biotechnology - Benjamin Britten Lounge, 3^rd Floor

Connect with leading biotechnology companies, services and regions during a two-day span during which they will be showcased.

. Current Partnering - United Kingdom
. Current Agreements - United Kingdom
. Deloitte Recap LLC - USA
. Hungarian Investment and Trade Agency (HITA) - Hungary
. Health Protection Agency - United Kingdom
. AWEX - Wallonia Foreign Trade and Investment Agency - Belgium
. University of Nottingham - United Kingdom
. Trinity College Institute of Neuroscience (TCIN) - Ireland
. Merrill Datasite - United Kingdom
. EuropaBio - Belgium
. UBIFrance - United Kingdom
. TransPerfect Trial Interactive - USA
. Flanders Investment & Trade - Belgium
. Cancer Research UK - United Kingdom
. International Trade Branch, Ontario Ministry of Economic Development and Trade - Canada
. Brussels Life Tech - Belgium

11:15-12:15  Workshop 3 | Cooley - Guild Room, 3M Floor

Title: International Deal-making – The Details of Key Business Provisions and Deal Points

This “hands on” Workshop focuses on the critical elements of cross-border partnering transactions. In the current pharmaceutical business environment, international partnering deals involving territory-specific or multi-region rights, often coupled with co-development programs or retained product rights, has become very prevalent. This Panel of Cooley partnering experts will analyze and discuss deal provisions that are key to successful international deals, and will include an evaluation and discussion of a number of interesting recent deals.

Chair: Mr. Barclay Kamb, Partner, Cooley LLP
Speaker: Mr. Frederick Dorey, Special Counsel, Cooley LLP
Speaker: Dr. Marya Postner, Partner, Cooley LLP
Speaker: Mr. Glen Slato, Partner, Cooley LLP

11:30-12:30  Pharmaceutical Presentations | Stream 1 - Abbey Room West Room, 4^th Floor

In these presentations, the speakers will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.

11:30 - 11:55	Novo Nordisk
	Title: Novo Nordisk - Partnering for innovation in Protein-based Therapeutics and Technologies Description: Novo Nordisk Company Presentation Speaker: Tomas Landh, Director Strategy and Sourcing, Novo Nordisk
12:00 - 12:25	Merck
	Title: Partnering with Merck Description: Merck Company Presentation Speaker: Manfred Horst, Director, Scientific Liaison, Licensing and External Research Europe, Merck

11:30-12:30  Pharmaceutical Presentations | Stream 2 - Abbey Room East Room, 4^th Floor

In these presentations, the speakers will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.

11:30 - 11:55	Roche
	Title: Partnering at Roche Description: Roche Company Presentation Speaker: Andrew Sleight, Global Head of CV and Met Partnering
12:00 - 12:25	Novartis
	Title: Partnering with Novartis Description: Novartis Company Presentation Speaker: Axel Maibuecher, Head of Search and Evaluation for Integrated Hospital Care, Global Business Development & Licensing, Novartis Pharma AG

11:30-12:30  Pharmaceutical Presentations | Stream 3 - Henry Moore East Room, 4^th Floor

In these presentations, the speakers will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.

11:30 - 11:55	AstraZeneca
	Title: Partnering with AstraZeneca Description: AstraZeneca Partnering Presentation Speaker: Beverley Jordan, Vice President, SPBD Finance & Enabling Operations, AstraZeneca
12:00 - 12:25	Gloria Pharmaceuticals
	Title: Partnering with Gloria Pharmaceuticals Description: Gloria Pharmaceuticals Company Presentation Speaker: Viswanath Vaidyanathan, General Manager - International Business Development, Gloria Pharmaceuticals

11:30-12:30  Pharmaceutical Presentation | Stream 4 - Henry Moore West Room, 4^th Floor

In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.

11:30 - 11:55	Astex Pharmaceuticals
	Title: Partnering with Astex Description: Astex Company Presentation Speaker: Martin Buckland, Chief Business Officer, Astex Pharmaceuticals

12:30-13:30  Hot Buffet Lunch - Seated: 5^th Floor | Standing: 3^rd Floor

Continue your networking over a delicious lunch.

Seated: Elizabeth Windsor Room, 5^th Floor
Standing: Benjamin Britten Lounge, 3^rd Floor

13:30-16:00  Podium Presentations | Stream 1 - Abbey Room West, 4^th Floor

In this dedicated presentation room, companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

13:30 Durata Therapeutics Inc. - USA
13:45 Resverlogix Corporation - Canada
14:00 Intercell AG - Austria
14:15 Aquapharm BioDiscovery Ltd - United Kingdom
14:30 Transgene S.A. - France
14:45 Bachem AG - Switzerland
15:00 GenKyoTex - Switzerland
15:15 Pulmatrix - USA
15:30 BioFilm Control - France
15:45 Lamellar Biomedical Limited - United Kingdom

13:30-16:00   Podium Presentations | Stream 2 - Abbey Room East, 4^th Floor

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

13:30 Vivacta Limited - United Kingdom
13:45 Silence Therapeutics plc - Germany
14:00 Moberg Derma AB - Sweden
14:15 Synovo GmbH - Germany
14:30 Ardea Biosciences - USA
14:45 Curis Inc. - USA
15:00 Hyphens Pharma - Singapore
15:15 Haemostatix Ltd. - United Kingdom
15:30 Sangart - USA
15:45 Molplex Ltd. - United Kingdom

13:30-16:00  Podium Presentations | Stream 3 - Henry Moore East, 4^th Floor

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

13:30 Ingentyx - Denmark
13:45 Biotie Therapies - Finland
14:00 Xention Limited - United Kingdom
14:15 CalciMedica - USA
14:30 Hermo Pharma Ltd. - Finland
14:45 3M Drug Delivery Systems - United Kingdom
15:00 Flamel Technologies SA - USA
15:15 Armour Therapeutics, Inc. - Canada
15:30 The Medicines Company - Switzerland
15:45 Ardelyx - USA

13:30-16:00  Podium Presentations | Stream 4 - Henry Moore West, 4^th Floor

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

13:30 Leads To Development (L2D) Services - France
13:45 ImmunID Technologies - France
14:15 Thrasos - Canada
14:30 Wellcome Trust - United Kingdom
15:00 Unisensor A/S - Denmark
15:15 Medivir - Sweden
15:45 Activaero - Germany

14:00-15:00  Leadership Session 3 | TVG - Whittle Room, 3^rd Floor

Title: European Biotech CEO Perspective

A panel comprised of CEOs of European Biotechnology companies will discuss their perspectives of the realities they face in 2011. Huge changes have affected biotech companies in Europe this year, including ongoing financial uncertainties and market turmoil, the downsizing of big pharma companies, fewer vc funds, and more. Who better to talk about how these, and other factors, affect the present and future of the European bioindustry? A group of seasoned CEOs will provide insight into their thinking, planning, and actions, to guide their companies to growth and prosperity.

Chair: Dr. Robert Lee Kilpatrick, Partner, TVG
Speaker: Dr. Edwin Moses, Chief Executive Officer & Chairman of the Board, Ablynx
Speaker: Mr. Onno van de Stolpe, Chief Executive Officer, Galapagos

15:00-16:00  Workshop 4 | European Biotechnology Network - Guild Room, 3M Floor

Title: Managing Partnerships in Healthcare Biotechnology

The final workshop looks at the key points in creating and delivering partnerships. Partnerships are effective when planned long term, with a strong framework and always with an eye on the prize. Topics within this session include managing IP, understanding partner needs before you start, risk management for partnerships and bringing company cultures together.

Chair: Dr. Claire Skentelbery, Secretary General, European Biotechnology Network
Speaker: Mr. Edward Agne, President, The Communications Strategy Group Inc.
Speaker: Ms. Lin Bateson, Executive Director, Biopartner.co.uk
Speaker: Mr. Jean-Pol Detiffe, Chief Executive Officer, DNAVISION SA
Speaker: Dr. George Rahim, Head of Alliance Management and Operations, GlaxoSmithKline Biologicals
Speaker: Dr. Mark Treherne, Chief Executive, Senexis

16:00-17:00  Closing Session - Whittle Room, 3^rd Floor

Title: Opportunities and Challenges in Pharmaceutical Partnering

The selection of an ideal partner, signing of the deal and managing the ongoing relationship to a successful technical and commercial conclusion presents a significant challenge to both parties.

The partnering panel, comprised of senior pharmaceutical executives from in licensing, out licensing and alliance management functions will discuss and share the key features and activities they believe are most important for success with reference to the business climate of today.

Chair: Mr. Jason Rushton, Director, Deloitte LLP
Speaker: Dr. Chris Britten, Business Development, Astellas Pharma Europe Limited
Speaker: Dr. Lubor Gaal, Head of Europe, Search and Evaluation, Strategic Transactions Group, Bristol-Myers Squibb Co.
Speaker: Dr. Axel Maibuecher, Head of Search and Evaluation for Integrated Hospital Care, Global Business Development & Licensing , Novartis Pharma AG
Speaker: Dr. Rob Pinnock, Director, Scientific Liaison, Licensing & External Research Europe, Merck/MSD

17:00-18:00  Farewell Drinks Reception - Elizabeth Windsor Room, 5^th Floor

Title: Sponsored by Belgium

Celebrate the launch of BioPartnering Future Europe (BPFE), October 7-9, 2012 in Brussels, Belgium - moving towards its 20th year of continuous service.